About Reach Neuro
Reach Neuro makes an implanted medical device for stroke survivors who have lost movement in an arm or hand. It delivers small electrical pulses to the spinal cord to help the nervous system restore voluntary control of the shoulder, arm, and hand. Each patient's stimulation is tuned to their needs, and the approach may also serve people with other neurological disorders.
Reach Neuro operates from Providence, Rhode Island. Jennifer Ernst is CEO, and Jordi Parramon is chairman.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Oct 30, 2026 | Nov 17, 2026 | $2,000,000fully sold | 12 | $166K | Equity, Conversion of SAFE'sRule 506(b) | Form D ↗ |
| Jul 29, 2022 | Aug 19, 2022 | $200,000of $1.5M target | 1 | $200K | Simple Agreements for Future Equity (SAFEs)Rule 506(b) | Form D ↗ |
| Total, two offerings | $2,200,000 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Reach Neuro's Form D filed Nov 17, 2026.




Earlier filings also listed
- Peter Gerszten · director and promoterLast listed on the Form D that Reach Neuro filed on August 19, 2022; on 1 of its 2 filings.
- Marc Powell · president and directorLast listed on the Form D that Reach Neuro filed on August 19, 2022; on 1 of its 2 filings.
Why Investors Backed Reach Neuro
The investment case centers on lasting paralysis after the early stroke-recovery window, when Reach Neuro sees no standard long-term care. Reach Neuro brings early human gains, an NIH-funded clinical program, and FDA Breakthrough Device status to that gap. [2]
“The Breakthrough Device designation is an incredible opportunity to work closely with FDA experts to expedite the clinical translation of the Avantis system.”
Origin and Team
The company began in 2021 by spinning out research from the University of Pittsburgh and Carnegie Mellon University. Marc Powell served as chief executive officer and co-founder when Avantis received its designation in 2023. Reach Neuro is an alumnus of SOSV's IndieBio startup program. [2]
Product and Technology
Its Avantis implant places an electrode array in the neck portion of the spinal cord. That area contains neurons controlling shoulder, arm, and hand movement. An implanted generator sends small electrical pulses through a plan tuned to each patient. [1][2]
In the first two study participants, grip strength improved 40% and 108%. Joint strength rose by as much as 124%, and reaching was 30% to 40% faster. Participants lifted objects, ate with a fork, and opened a lock. [2]
Early evidence included benefit as late as nine years after stroke, beyond the usual six-month therapy window. Researchers observed some gains lasting one month without stimulation. The approach strengthened muscle activity without unintended movements. [2]
Milestones
Scroll table to see all columns →
| Date | What happened | Source | Coverage |
|---|---|---|---|
| Jun 2026 | A feasibility trial assessed spinal-cord stimulation for arm movement in people with lasting weakness on one side after a stroke. | [1] | — |
| Apr 10, 2023 | The FDA granted Breakthrough Device designation to Avantis. | [2] | — |
| Apr 2023 | SOSV included Reach Neuro in its 2023 Human Health 100. | [1] | — |
| 2023 | The team published the first two trial participants' results in Nature Medicine. | [2] | — |
| 2023 | The technology was undergoing an NIH-funded clinical trial with UPMC. | [2] | — |
Market
Reach Neuro estimates that 800,000 people in the United States have a stroke each year, with nearly half developing some lasting paralysis. It also puts the population living with post-stroke disability near 7.5 million. [2]
Reach Neuro sees no standard care for chronic post-stroke paralysis. It links poor access to later therapy with limited evidence of benefit after the first three to six months. [2]
We wrote this summary from public statements by Reach Neuro and its investors. It is not investment advice.
Sources
- CompanyReach Neuro company website · linked above ↑
- PressReach Neuro FDA Breakthrough Device release
- SECReach Neuro Form D, filed 2026-11-17 · linked above ↑
- SECReach Neuro Form D, filed 2022-08-19 · linked above ↑
- SECReach Neuro, Inc. filing history
